PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT
This one-hour Internet symposium will review and discuss the clinical management of Hepatitis C co-infection in HIV-positive patients. This symposium will feature an interview of Mark Sulkowski, MD, one of the leading experts in Hepatitis and HIV co-infection, by Calvin Cohen, MD, MS, Research Director of CRI New England and Clinical Instructor at Harvard Medical School.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals actively involved in the treatment and management of patients with hepatitis and HIV co-infection.
Back to Top
After completing this activity, participants should be able to:
Employ clinical decisions regarding the use of new therapies becoming available for HCV, including protease inhibitors, in HIV/HCV co-infected patients;
Apply key clinical research evaluating ART regimens and strategies in HIV patients with hepatitis C co-infection;
Use data regarding the assessment and management of hepatitis C co-infection to improve the overall health of HIV-positive patients.
Release Date: May 24, 2011
Expiration Date: May 24, 2012
PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT
Estimated time to complete the On-Demand Web Symposium: 1 hour
Media: Internet
Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Baltimore, Maryland
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Calvin Cohen, MD, MS
|
|
Mark Sulkowski, MD
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating and receiving credit for this activity. During the period, May 24, 2011 through May 24, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the post-test online at: www.cmeuniversity.com
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
